Trial · NCT03508687
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 70
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Fasting Serum Triglyceride (at 12 Weeks) | Group 1: 300 mg Gemcabene Daily Week 1-24 | -0.44 | Full Range -41.27 to 40.38 | percent change | |
| Change in Fasting Serum Triglyceride (at 12 Weeks) | Group 2: 600mg Gemcabene Daily Week 12-24 | -20.27 | Full Range -53.98 to 12.77 | percent change | |
| Change in Fasting Serum Triglycerides (Through 24 Weeks) | Group 1: 300 mg Gemcabene Daily Week 1-24 | Baseline to average of W6, W12, W24 | 9.25 | Full Range -68.50 to 87.00 | mg/dL |
| Change in Fasting Serum Triglycerides (Through 24 Weeks) | Group 2: 600mg Gemcabene Daily Week 12-24 | Baseline to average of W6, W12, W24 | -126.22 | Full Range -252.17 to -10.50 | mg/dL |
| Change in Fasting Serum Triglycerides (Through 24 Weeks) | Group 1: 300 mg Gemcabene Daily Week 1-24 | Baseline to W12 | -10.75 | Full Range -126.50 to 105.00 | mg/dL |
| Change in Fasting Serum Triglycerides (Through 24 Weeks) | Group 2: 600mg Gemcabene Daily Week 12-24 | Baseline to W12 | -189.33 | Full Range -305.00 to 32.50 | mg/dL |
| Percent Change in Fasting Serum Triglycerides (Through 24 Weeks) | Group 1: 300 mg Gemcabene Daily Week 12-24 | Baseline to average of W6, W12, and W24 | 5.56 | Full Range -22.35 to 33.46 | percent change |
| Percent Change in Fasting Serum Triglycerides (Through 24 Weeks) | Group 2: 600mg Gemcabene Daily Week 12-24 | Baseline to average of W6, W12, and W24 | -18.91 | Full Range -45.15 to -4.15 | percent change |
| Percent Change in Fasting Serum Triglycerides (Through 24 Weeks) | Group 1: 300 mg Gemcabene Daily Week 12-24 | Baseline to Week 12 | -0.44 | Full Range -41.27 to 40.38 | percent change |
| Percent Change in Fasting Serum Triglycerides (Through 24 Weeks) | Group 2: 600mg Gemcabene Daily Week 12-24 | Baseline to Week 12 | -19.91 | Full Range -52.91 to 12.77 | percent change |
| Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Group 1: 300 mg Gemcabene Daily Week 1-24 | Baseline to Week 12 | 2.71 | Full Range 0.37 to 5.05 | % PDFF |
| Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Group 2: 600mg Gemcabene Daily Week 12-24 | Baseline to Week 12 | 1.01 | Full Range -4.22 to 7.76 | % PDFF |
| Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Group 1: 300 mg Gemcabene Daily Week 1-24 | Baseline to Week 24 | 12.75 | Full Range 9.53 to 15.96 | % PDFF |
| Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Group 2: 600mg Gemcabene Daily Week 12-24 | Baseline to Week 24 | -1.27 | Full Range -8.54 to 8.20 | % PDFF |
| Percent Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Group 1: 300 mg Gemcabene Daily Week 1-24 | Baseline to Week 12 | 25.66 | Full Range 2.10 to 49.22 | percent change in liver fat |
| Percent Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Group 2: 600mg Gemcabene Daily Week 12-24 | Baseline to Week 12 | 11.57 | Full Range -31.73 to 69.22 | percent change in liver fat |
| Percent Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Group 1: 300 mg Gemcabene Daily Week 1-24 | Baseline to Week 24 | 104.88 | Full Range 54.21 to 155.56 | percent change in liver fat |
| Percent Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Group 2: 600mg Gemcabene Daily Week 12-24 | Baseline to Week 24 | -3.36 | Full Range -64.21 to 73.15 | percent change in liver fat |
| Change in Liver Fibrosis | Group 1: 300 mg Gemcabene Daily Week 1-24 | Baseline to Week 12 | -0.63 | Full Range -0.63 to -0.63 | kPA |
| Change in Liver Fibrosis | Group 2: 600mg Gemcabene Daily Week 12-24 | Baseline to Week 12 | 0.96 | Full Range -0.05 to 1.73 | kPA |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03508687/results